Eliem Therapeutics, Inc. (NASDAQ:ELYM – Get Free Report)’s stock price dropped 2.8% during trading on Monday . The company traded as low as $6.95 and last traded at $7.18. Approximately 491,605 shares were traded during mid-day trading, an increase of 1% from the average daily volume of 486,688 shares. The stock had previously closed at $7.39.
Eliem Therapeutics Trading Down 2.8%
The business’s 50 day simple moving average is $5.16 and its two-hundred day simple moving average is $3.31. The firm has a market capitalization of $213.62 million, a PE ratio of -13.55 and a beta of -0.39.
About Eliem Therapeutics
Eliem Therapeutics, Inc is a clinical‐stage biotechnology company focused on the development of novel therapeutics for the treatment of neurological and neuropsychiatric disorders. The company’s scientific approach is centered on proprietary peptide and small‐molecule drug candidates designed to modulate central nervous system pathways. By leveraging targeted delivery and receptor‐specific activity, Eliem seeks to address unmet medical needs in areas such as pain management, spasticity and other debilitating sequelae of spinal cord injury.
The company’s most advanced program, ELI-200, is being investigated as a potential treatment for spasticity and neuropathic pain associated with spinal cord injury.
Read More
- Five stocks we like better than Eliem Therapeutics
- Gold Shock Coming March 18?
- Buy this Gold Stock Before May 15th, 2026
- America’s 1776 happening again
- J.P. Morgan is betting on this coin
- Central banks just did something they haven’t done since 1967
Receive News & Ratings for Eliem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eliem Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
